Drug intelligence / Profile preview

ivosidenib + 7+3

Development stage: Preclinical
Lead developer: Servier Pharmaceuticals
Modality: Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral, Intravenous

Overview

Ivosidenib + 7+3 is an investigational combination therapy being developed by Servier and Symphogen for the treatment of newly diagnosed Acute Myeloid Leukemia (AML) harboring IDH1 mutations. The regimen combines ivosidenib, an oral small-molecule inhibitor of the mutant isocitrate dehydrogenase 1 (IDH1) enzyme, with the standard-of-care '7+3' induction chemotherapy, which consists of a seven-day continuous infusion of cytarabine and a three-day course of an anthracycline (typically daunorubicin). Ivosidenib functions by reducing the production of the oncometabolite 2-hydroxyglutarate (2-HG), thereby restoring normal cellular differentiation, while the chemotherapy components induce cytotoxic effects through DNA synthesis inhibition and intercalation. This combination aims to improve complete remission rates and overall survival in IDH1-mutant AML patients.

Brand names: Tibsovo
Other names: Ivosidenib + cytarabine + anthracyclineIvosidenib + 7+3 regimen

Targets

OATP1B1 (Organic anion transporting polypeptide 1B1)IDH1 (Isocitrate dehydrogenase [NADP] cytoplasmic)CYP3A4 (Cytochrome P450 3A4)SLCO1B3 (Organic anion transporting polypeptide 1B3)SLC22A8 (Organic anion transporter 3)CYP2C9 (Cytochrome P450 family 2 subfamily C member 9)CYP2C8 (Cytochrome P450 2C8)

Beyond the preview

Go deeper on ivosidenib + 7+3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ivosidenib + 7+3.

Explore the full profile